bioverà technology overview

---

A Patent-Pending Sensing and Stimulation Platform for Respiratory Intelligence

bioverà has developed a new category of wearable technology: active respiratory intelligence at the nasal pathway. The platform detects physiological instability before it escalates and responds in real time through a closed-loop system of sensing, interpretation, and non-arousing stimulation.

The intellectual property covers the core sensing and stimulation layer. It is designed for integration across sleep health devices, wearable technology platforms, and driver safety systems.

The Platform

bioverà operates at the nasal valve, the narrowest and highest-fidelity point in the respiratory system. Acting upstream means detecting instability earlier, responding faster, and requiring less intervention than chest, wrist, or throat-based systems. No prior wearable device has combined sensing, interpretation, and closed-loop stimulation at this location in a single system.

The platform integrates acoustic snore detection, airflow sensing, oxygen saturation monitoring, heart rate variability, motion and posture tracking, and optional nitric oxide sensing. On-device AI classifies user state in real time and adjusts stimulation parameters dynamically without requiring cloud connectivity.

The IP

bioverà holds a patent-pending position covering a wearable nasal expansion and airway stimulation system with the following claims:

A multimodal transducer system at the nasal valve region including vibrotactile, electromagnetic, piezoelectric, and pneumatic actuation, individually or in combination.

Closed-loop control that adapts stimulation based on real-time sensor input including airflow, acoustics, oximetry, and posture.

Nitric oxide modulation in nasal tissue through localized stimulation, a mechanism with significant implications for both respiratory and cardiovascular health.

AI-driven personalization that builds an individual respiratory baseline and optimizes stimulation parameters over time.

Stimulation delivered within a frequency range clinically validated to produce physiological response without triggering cortical arousal, a non-negotiable requirement for overnight use.

The claims are broad enough to cover the core technology layer, not just a single product form. This makes the IP relevant across multiple device categories and integration scenarios.

Three Integration Opportunities

Sleep Health: the platform adds active upstream respiratory intervention to existing CPAP alternatives, oral appliance ecosystems, and smart sleep wearables. The non-arousing stimulation approach addresses the core compliance problem that defines this market.

Wearable Technology: the nasal pathway sensing layer provides biometric data quality not achievable from wrist or finger-based sensors. Heart rate variability, respiratory rate, oxygen saturation, and stress state can be captured with greater fidelity and earlier signal than current wearable platforms provide.

Driver and Fleet Safety: respiratory patterns carry measurable signatures of fatigue and cognitive impairment. bioverà detects these in real time and delivers non-disruptive intervention before safety is compromised. Future configurations integrate transdermal alcohol concentration sensing for continuous impairment detection without driver interaction.

Scientific Validation

Three independent bodies of peer-reviewed research underpin the platform.

Trigeminal Nerve Stimulation and Fatigue, Neuroscience 2025. Chen Cheng et al. DOI: 10.1016/j.neuroscience.2024.12.044. External stimulation of the trigeminal nerve, which runs through the nasal region, produced improved alertness, reduced cortisol, and zero arousal in fatigued subjects.

Vibrotactile Therapy for Sleep Apnea, Thorax 2023. Meta-analysis. Approximately 43% reduction in apnea events. No increase in arousal index.

SNORAP Closed-Loop Study, 2017. Microphone-triggered tactile stimulation produced approximately 51% reduction in snoring and apnea severity with zero EEG-measured arousals.

bioverà extends these validated principles by acting at the nasal valve specifically, operating continuously in real time, and combining all three functions in a single patent-pending system.

Prototype Validation

Early prototypes have demonstrated reliable detection of airflow instability and snoring, rapid closed-loop response to breathing restriction, consistent overnight operation across body positions and sleep stages, and stable sensor performance under extended use conditions. These results establish technical feasibility and support continued development toward clinical validation.

Licensing and Partnership Inquiries

bioverà is actively pursuing licensing and integration partnerships across sleep health, wearable technology, and driver safety verticals. The platform is designed to function as a core technology layer within existing product ecosystems, not as a competing consumer brand.

For partnership inquiries contact: partnerships@biovera.ai